Stockpolly
Search
CVRX · NASDAQ · Medical - Devices

CVRx (CVRX)

Implantable Barostim therapy improves symptoms for eligible heart-failure patients.

$3.10
Pre-market+0.03 (+0.98%)
At close$3.07(+0.99%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue111111121315121415161516
Cost of revenue222222222222
Gross profit9109101113101113141314
181931242423242625252527
Research & development323333323333
Selling, general & administrative161728212221212322222224
Operating income−10−10−22−14−13−10−13−14−12−11−12−13
11000000−1−1−1−1
Interest expense011112111122
Other non-operating income−1−1−1−1−1−1−1−1−1−1−1−1
Income before tax−9−9−22−14−13−11−14−15−13−12−13−14
Income tax expense000000000000
Net income from continuing operations−9−9−22−14−13−11−14−15−13−12−13−14
Other adjustments000000000000
Net income−9−9−22−14−13−11−14−15−13−12−13−14
EPS, basic−$0.43−$0.44−$1.04−$0.65−$0.57−$0.43−$0.53−$0.57−$0.49−$0.46−$0.50−$0.53
EPS, diluted−$0.43−$0.44−$1.04−$0.65−$0.57−$0.43−$0.53−$0.57−$0.49−$0.46−$0.50−$0.53
Weighted average shares, basic212121222323262626262627
Weighted average shares, diluted212121222323262626262627
EBITDA−8−8−21−13−12−9−12−13−11−10−11−12
Depreciation & amortization000000000000
EBIT−8−9−21−13−12−9−12−13−11−11−12−12